CY1113298T1 - Ανασυνδυασμενα αντισωματα υψηλης ισχυος και μεθοδος παραγωγης αυτων - Google Patents
Ανασυνδυασμενα αντισωματα υψηλης ισχυος και μεθοδος παραγωγης αυτωνInfo
- Publication number
- CY1113298T1 CY1113298T1 CY20121100934T CY121100934T CY1113298T1 CY 1113298 T1 CY1113298 T1 CY 1113298T1 CY 20121100934 T CY20121100934 T CY 20121100934T CY 121100934 T CY121100934 T CY 121100934T CY 1113298 T1 CY1113298 T1 CY 1113298T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- neutralizing
- producing
- disclosed
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000011084 recovery Methods 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Abstract
Κοινοποιούνται αντισώματα υψηλής ισχύος συμπεριλαμβανομένων ανοσολογικά δραστικών κλασμάτων αυτών, που έχουν υψηλές σταθερές κινητικού προσεταιρισμού και προαιρετικά υψηλές χημικές συγγένειες, μαζί με μεθόδους για την παραγωγή τέτοιων αντισωμάτων. Τα αντισώματα υψηλής ισχύος που κοινοποιούνται στην παρούσα είναι είτε τύπου εξουδετέρωσης ή μη εξουδετέρωσης και έχουν ιδιαιτερότητα για τα αντιγόνα που εμφανίζονται από μικροοργανισμούς, ειδικότερα ιούς, καθώς και αντιγονικές περιοχές που εμφανίζονται πάνω σε καρκινικά κύτταρα και σε διάφορους τύπους τοξινών και τα προϊόντα τοξινών. Περιγράφονται επίσης διαδικασίες για την παραγωγή αντισωμάτων εξουδετέρωσης υψηλής ισχύος και αύξησης της ισχύος των ήδη υφισταμένων αντισωμάτων εξουδετέρωσης. Κοινοποιούνται μέθοδοι χρήσης των εν λόγω αντισωμάτων στην πρόληψη και/ ή την θεραπεία ασθενειών, ειδικότερα ασθενειών που επάγονται ή προκαλούνται από ιούς.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18625200P | 2000-03-01 | 2000-03-01 | |
EP01914657A EP1259547B1 (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113298T1 true CY1113298T1 (el) | 2016-04-13 |
Family
ID=22684221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100934T CY1113298T1 (el) | 2000-03-01 | 2012-10-05 | Ανασυνδυασμενα αντισωματα υψηλης ισχυος και μεθοδος παραγωγης αυτων |
Country Status (10)
Country | Link |
---|---|
US (2) | US7700735B2 (el) |
EP (3) | EP1259547B1 (el) |
JP (2) | JP2003525061A (el) |
AU (4) | AU2001240020B9 (el) |
CA (1) | CA2401652A1 (el) |
CY (1) | CY1113298T1 (el) |
DK (1) | DK1259547T3 (el) |
ES (1) | ES2390761T3 (el) |
PT (1) | PT1259547E (el) |
WO (1) | WO2001064751A2 (el) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2289550A3 (en) * | 2000-01-27 | 2012-02-15 | MedImmune, LLC | Ultra high affinity neutralizing antibodies |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
AU2001240020B9 (en) | 2000-03-01 | 2008-12-04 | Medimmune, Llc | High potency recombinant antibodies and method for producing them |
US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
AU1994402A (en) * | 2000-11-28 | 2002-06-11 | Mediummune Inc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
JP2005522996A (ja) * | 2001-11-02 | 2005-08-04 | セントカー・インコーポレーテツド | Rsvタンパク質、抗体、組成物、方法および使用 |
US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
JP2006500905A (ja) * | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化gm−csf抗体 |
JP4585968B2 (ja) * | 2002-05-10 | 2010-11-24 | パーデュー・リサーチ・ファウンデーション | EphA2アゴニストモノクローナル抗体およびその使用法 |
US20040028685A1 (en) * | 2002-05-10 | 2004-02-12 | Kinch Michael S. | EphA2 monoclonal antibodies and methods of use thereof |
US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
TW200501985A (en) * | 2002-07-25 | 2005-01-16 | Medimmune Inc | Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies |
US7541033B2 (en) | 2003-01-24 | 2009-06-02 | Applied Molecular Evolution, Inc. | Humanized anti-IL-1β antibodies |
AU2004229543A1 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Llc | EphA2 and non-neoplastic hyperproliferative cell disorders |
US20050049176A1 (en) * | 2003-04-11 | 2005-03-03 | Kiener Peter A. | EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
US7070786B2 (en) | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
AU2005214988A1 (en) * | 2004-02-17 | 2005-09-01 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
WO2006046935A1 (en) * | 2004-10-22 | 2006-05-04 | Applied Molecular Evolution, Inc | Methods of optimizing antibody variable region binding affinity |
WO2006050166A2 (en) * | 2004-10-29 | 2006-05-11 | Medimmune, Inc. | Methods of preventing and treating rsv infections and related conditions |
US20100040606A1 (en) * | 2006-03-06 | 2010-02-18 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
US20100166746A1 (en) * | 2006-12-04 | 2010-07-01 | Medlmmune Way | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
CA2678628A1 (en) * | 2007-03-06 | 2008-09-12 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
NZ703668A (en) | 2007-06-27 | 2016-07-29 | Us Sec Dep Of Health And Human Services | Complexes of il-15 and il-15ralpha and uses thereof |
US8187601B2 (en) * | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
US8775090B2 (en) | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
WO2010085590A1 (en) | 2009-01-23 | 2010-07-29 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria |
US8852608B2 (en) | 2009-02-02 | 2014-10-07 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
CA2769822C (en) | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
WO2011062560A1 (en) * | 2009-11-19 | 2011-05-26 | National University Of Singapore | Method for producing t cell receptor-like monoclonal antibodies and uses thereof |
EP2542696B1 (en) | 2010-03-01 | 2016-09-28 | Caris Life Sciences Switzerland Holdings GmbH | Biomarkers for theranostics |
JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
HUE049154T2 (hu) | 2011-05-04 | 2020-09-28 | Omeros Corp | Készítmények a MASP-2-függõ komplement-aktiválás gátlására |
WO2012162257A2 (en) | 2011-05-20 | 2012-11-29 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
TWI646111B (zh) | 2011-05-20 | 2019-01-01 | 艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途 |
KR102128628B1 (ko) | 2011-05-20 | 2020-06-30 | 앨더바이오 홀딩스 엘엘씨 | 설사의 만성 및 급성 형태를 치료 또는 예방하기 위한 항-cgrp 또는 항-cgrp-r 항체 또는 항체 단편의 용도 |
TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法 |
US11161891B2 (en) | 2015-12-09 | 2021-11-02 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
EP3528840A1 (en) | 2016-10-21 | 2019-08-28 | Adimab, LLC | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
WO2018075954A2 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
WO2018075974A2 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE7855T1 (de) | 1980-07-01 | 1984-06-15 | National Research Development Corporation | Herstellung von virusantigenen. |
WO1982003089A1 (en) | 1981-03-06 | 1982-09-16 | Lennox Edwin Samuel | Monoclonal antibody |
ATE37983T1 (de) * | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
US5340926A (en) | 1983-03-25 | 1994-08-23 | Celltech, Limited | Process for the recovery of recombinantly produced protein from insoluble aggregate |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US5332805A (en) | 1984-02-03 | 1994-07-26 | Celltech Limited | Process for the recovery of recombinantly produced chymosin from insoluble aggregate |
US5128326A (en) * | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
FR2590674B1 (fr) | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | Nouveaux reactifs de diagnostic |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US4717766A (en) | 1986-01-27 | 1988-01-05 | Miles Laboratories, Inc. | Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin |
US4659563A (en) | 1986-01-27 | 1987-04-21 | Miles Laboratories, Inc. | High titer anti-respiratory syncytial virus intravenous immune globulin |
US5271927A (en) | 1986-02-13 | 1993-12-21 | Celltech Limited | Antibody conjugates with macrocyclic ligands |
US5468606A (en) | 1989-09-18 | 1995-11-21 | Biostar, Inc. | Devices for detection of an analyte based upon light interference |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4800078A (en) * | 1987-05-28 | 1989-01-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb |
US4880078A (en) * | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
GB8719041D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
US4916893A (en) * | 1987-09-02 | 1990-04-17 | Sundstrand Corporation | Multipurpose auxiliary power unit |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5223254A (en) | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
JP2716503B2 (ja) | 1987-12-23 | 1998-02-18 | ジ・アップジョン・カンパニー | ヒト呼吸系シンシチウムウイルスの糖蛋白類の免疫原性セグメントを含有するキメラ糖蛋白類 |
WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
US5183657A (en) | 1988-03-11 | 1993-02-02 | Celltech Limited | Antibodies for use in antilymphocyte antibody therapy |
JPH01268646A (ja) | 1988-04-20 | 1989-10-26 | Meiji Milk Prod Co Ltd | 抗腫瘍剤 |
US5137804A (en) | 1988-05-10 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Assay device and immunoassay |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5354554A (en) | 1989-02-10 | 1994-10-11 | Celltech Limited | Crosslinked antibodies and processes for their preparation |
US6093872A (en) | 1989-05-05 | 2000-07-25 | Systemix, Inc. | Extended human hematopoiesis in a heterologous host |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
US5518725A (en) | 1989-09-25 | 1996-05-21 | University Of Utah Research Foundation | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination |
AU642932B2 (en) * | 1989-11-06 | 1993-11-04 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5279935A (en) | 1990-03-01 | 1994-01-18 | Becton, Dickinson And Company | Method of immunossay including deactivation of endogenous alkaline phosphatase |
ES2090332T3 (es) | 1990-05-03 | 1996-10-16 | Systemix Inc | Tejido linfoide humano en un hospedador inmunocomprometido. |
US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
JP3672306B2 (ja) * | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
WO1992018652A1 (en) | 1991-04-22 | 1992-10-29 | Massachusetts Health Research Institute, Inc. | Process of screening plasma samples for effective antibody titers against respiratory viruses |
DE69232706T2 (de) * | 1991-05-01 | 2002-11-28 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
CA2044940A1 (en) | 1991-06-10 | 1992-12-11 | Inder M. Verma | Transdominant negative proto-oncogene |
US5240694A (en) | 1991-09-23 | 1993-08-31 | University Of Virginia | Combined antiviral and antimediator treatment of common colds |
US5418136A (en) | 1991-10-01 | 1995-05-23 | Biostar, Inc. | Devices for detection of an analyte based upon light interference |
EP0614530B1 (en) * | 1991-11-15 | 1998-03-04 | Cornell Research Foundation, Inc. | Indirect immunoassay for dioxinlike compounds |
US20020102257A1 (en) * | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5667988A (en) * | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
EP0671927B1 (en) | 1992-09-16 | 2003-01-15 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
US6685942B1 (en) * | 1993-12-10 | 2004-02-03 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
EP0680337A4 (en) | 1993-01-12 | 1997-07-30 | Anthony George Gristina | METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY. |
US5934272A (en) * | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5424189A (en) | 1993-03-05 | 1995-06-13 | Kansas State University Research Foundation | Bovine respiratory syncytial virus detection and primers |
CA2167835A1 (en) * | 1993-07-30 | 1995-02-09 | Richard A. Weltzin | Monoclonal iga antibody against respiratory syncytial virus |
US5506209A (en) | 1994-05-26 | 1996-04-09 | Abbott Laboratories | Product for inhibition of infection of mammalian cells by respiratory syncytial virus |
US5538952A (en) | 1994-05-26 | 1996-07-23 | Abbott Laboratories | Inhibition of infection of mammalian cells by respiratory syncytial virus |
US5538733A (en) | 1994-07-07 | 1996-07-23 | Willmar Poultry Company, Inc. | Method of priming an immune response in a one-day old animal |
US5792456A (en) * | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
AU710347B2 (en) * | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
CA2230127A1 (en) * | 1995-09-18 | 1997-03-27 | Intracel Corporation | Neutralizing monoclonal antibodies to respiratory syncytial virus |
DK0885002T3 (da) * | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
FR2758331B1 (fr) | 1997-01-14 | 1999-03-05 | Univ Bourgogne | Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux |
US6590079B2 (en) * | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US6117980A (en) * | 1997-02-21 | 2000-09-12 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7229619B1 (en) * | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
EP2289550A3 (en) * | 2000-01-27 | 2012-02-15 | MedImmune, LLC | Ultra high affinity neutralizing antibodies |
AU2001240020B9 (en) | 2000-03-01 | 2008-12-04 | Medimmune, Llc | High potency recombinant antibodies and method for producing them |
US20010034062A1 (en) * | 2000-02-09 | 2001-10-25 | Scott Koenig | Antibody gene therapy with adeno-associated viral vectors |
AU2001241918A1 (en) * | 2000-03-02 | 2001-09-12 | Med Immune, Inc. | Methods of enhancing activity of vaccines and vaccine compositions |
AU5345901A (en) | 2000-04-13 | 2001-10-30 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
ATE457177T1 (de) * | 2000-05-03 | 2010-02-15 | Medimmune Llc | Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe |
EP1152199B1 (de) | 2000-05-03 | 2005-07-27 | IPV Inheidener Produktions- und Vertriebsgesellschaft mbH | Thermobehälter |
US20020004046A1 (en) * | 2000-05-03 | 2002-01-10 | Johnson Leslie S. | Combination therapy of respiratory diseases using antibodies |
WO2001089562A1 (en) * | 2000-05-25 | 2001-11-29 | Medimmune, Inc. | F-protein epitope-based vaccine for respiratory syncytial virus infection |
WO2002011753A1 (fr) | 2000-08-04 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Preparations proteiniques a injecter |
US6565888B1 (en) * | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
AU1994402A (en) | 2000-11-28 | 2002-06-11 | Mediummune Inc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
US6818216B2 (en) * | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
WO2006034292A2 (en) | 2004-09-21 | 2006-03-30 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
WO2006050166A2 (en) | 2004-10-29 | 2006-05-11 | Medimmune, Inc. | Methods of preventing and treating rsv infections and related conditions |
-
2001
- 2001-03-01 AU AU2001240020A patent/AU2001240020B9/en not_active Ceased
- 2001-03-01 WO PCT/US2001/006815 patent/WO2001064751A2/en active Application Filing
- 2001-03-01 DK DK01914657.0T patent/DK1259547T3/da active
- 2001-03-01 US US09/796,848 patent/US7700735B2/en not_active Expired - Fee Related
- 2001-03-01 EP EP01914657A patent/EP1259547B1/en not_active Expired - Lifetime
- 2001-03-01 AU AU4002001A patent/AU4002001A/xx active Pending
- 2001-03-01 CA CA002401652A patent/CA2401652A1/en not_active Abandoned
- 2001-03-01 PT PT01914657T patent/PT1259547E/pt unknown
- 2001-03-01 JP JP2001564244A patent/JP2003525061A/ja active Pending
- 2001-03-01 EP EP10010677A patent/EP2341074A1/en not_active Withdrawn
- 2001-03-01 EP EP10010678A patent/EP2341075A1/en not_active Withdrawn
- 2001-03-01 ES ES01914657T patent/ES2390761T3/es not_active Expired - Lifetime
-
2007
- 2007-05-08 AU AU2007202040A patent/AU2007202040B2/en not_active Ceased
-
2010
- 2010-02-09 JP JP2010026290A patent/JP2010162025A/ja active Pending
- 2010-02-17 US US12/707,527 patent/US8153133B2/en not_active Expired - Fee Related
- 2010-09-03 AU AU2010219289A patent/AU2010219289B2/en not_active Ceased
-
2012
- 2012-10-05 CY CY20121100934T patent/CY1113298T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001064751A3 (en) | 2001-12-20 |
EP1259547A2 (en) | 2002-11-27 |
US20020098189A1 (en) | 2002-07-25 |
AU2001240020B2 (en) | 2007-02-08 |
US8153133B2 (en) | 2012-04-10 |
AU2007202040A1 (en) | 2007-05-24 |
AU2001240020B9 (en) | 2008-12-04 |
WO2001064751A2 (en) | 2001-09-07 |
EP2341074A1 (en) | 2011-07-06 |
PT1259547E (pt) | 2012-10-15 |
AU2010219289B2 (en) | 2012-05-10 |
US7700735B2 (en) | 2010-04-20 |
DK1259547T3 (da) | 2012-10-15 |
EP2341075A1 (en) | 2011-07-06 |
AU2007202040B2 (en) | 2010-06-10 |
JP2003525061A (ja) | 2003-08-26 |
US20100239574A1 (en) | 2010-09-23 |
EP1259547B1 (en) | 2012-07-11 |
JP2010162025A (ja) | 2010-07-29 |
AU4002001A (en) | 2001-09-12 |
AU2010219289A1 (en) | 2010-09-30 |
CA2401652A1 (en) | 2001-09-07 |
ES2390761T3 (es) | 2012-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113298T1 (el) | Ανασυνδυασμενα αντισωματα υψηλης ισχυος και μεθοδος παραγωγης αυτων | |
CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
DK1294401T3 (da) | Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler | |
ES520692A0 (es) | Un procedimiento de preparacion de conjugados inmunoenzimaticos. | |
CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
DE69030172D1 (de) | Impfstoffe gegen Krebs und Infektionskrankheiten | |
CY1113044T1 (el) | Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων | |
CY1105389T1 (el) | Hpv-e7 ως αγωγη εναντι του ιου θηλωματων ανθρωπου | |
DE60134962D1 (de) | Anti-ccr4 antikörper und fragmente davon | |
EA200100224A1 (ru) | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 | |
ES2152421T3 (es) | Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas. | |
CY1111672T1 (el) | Παραγωγα αντιγονου σχετιζομενα με ογκους απο την οικογενεια των mage, τα οποια χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης με τ βοηθητικα επιτοπα και συνθεσεων για εμβολιασμο | |
CY1105963T1 (el) | Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης | |
CY1111591T1 (el) | Υβριδικη εκφραση πρωτεϊνων των neisseria | |
ECSP045470A (es) | Productos biologicos | |
GR3036229T3 (en) | Method for the production of antihuman antigen receptors and uses thereof | |
CY1114722T1 (el) | Αντιγονα στρεπτοκοκκου | |
ES2173314T3 (es) | Metodos y composiciones para la modificacion selectiva de acidos nucleicos. | |
DE60144240D1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
PL343245A1 (en) | Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses | |
ATE386105T1 (de) | Chimäre humane papillomavirus (hpv) l1 moleküle und deren verwendungen | |
CY1109125T1 (el) | Θεραπευτικα και διαγνωστικα anti-hsp 70 αντισωματα | |
CY1114069T1 (el) | Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 161p2f10b χρησιμα στη θεραπεια και ανιχνευση καρκινου | |
EP1708751A4 (en) | METHOD OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGEN EXPOSED ON APOPTOTIC TUMOR CELLS | |
ID21338A (id) | Metoda untuk menghasilkan kekebalan aktif dengan vaksin gabungan |